Skip to content

Trial Summary

This is an open label, Phase II, multicentre study evaluating the anti-tumour activity of continuous, low dose of panobinostat in patients with refractory solid tumours stratified by primary histology into osteosarcoma, malignant rhabdoid tumour/atypical teratoid rabdoid tumour (MRT/ATRT) and neuroblastoma.

Acronym:

NORTH

ACTRN/NCT /ethics:

ACTRN12618000321246

Scientific title:

A phase II study study of panobinostat in paediatric, adolescent and young adult patients with solid tumours including osteosarcoma, malignant rhaboidntumour/ atypical teratoid rhabdoid tumours and neuroblastoma.

Sponsor / Cooperative group:

ANZCHOG

Trial & Patient Characteristics

Cancer TypeOther
Trial TypeTreatment
PhasePhase II
Age RangeUnder 40 years of age
SexBoth
Tumour Stream -
Cancer StageAll stages
Anticipated Start Date2018-03-05
Anticipated End Date-

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 7074 2342
Principal InvestigatorNimit Singhal
Recruitment StatusRecruiting